Gemfibrozil is a potent lipid regulating drug whose major effects are to increase plasma high density lipoproteins (HDL) and to decrease plasma triglycerides (TG) in a wide variety of primary and secondary dyslipoproteinemias. Its mechanism of action is not clear. Six patients with primary familial endogenous hypertriglyceridemia with fasting chylomicronemia (type V lipoprotein phenotype) with concurrent subnormal HDL cholesterol levels (HDL deficiency) were treated initially by diet and once stabilized, were given gemfibrozil (1,200 mg/d). Each patient was admitted to the Clinical Research Center with metabolic kitchen facilities, for investigation of HDL and TG metabolism immediately before and after 8 wk of gemfibrozil treatment. Gemfibrozil significantly increased plasma HDL cholesterol, apolipoprotein (apo) AI, and apo AII by 36%, 29%, and 38% from base line, respectively. Plasma TG decreased by 54%. Kinetics of apo AI and apo AII metabolism were assessed by analysis of the specific radioactivity decay curves after injection of autologous HDL labeled with 125I. Gemfibrozil increased synthetic rates of apo AI and apo AII by 27% and 34%, respectively, without changing the fractional catabolic rates. Stimulation of apo AI and apo AII synthesis by gemfibrozil was associated with the appearance in plasma of smaller (and heavier These data suggest that gemfibrozil increases plasma HDL levels by stimulating their synthesis. Increased transport (turnover) of HDL induced by gemfibrozil may be significant in increasing tissue cholesterol removal in these patients.
Introduction
Gemfibrozil is a widely used potent lipid regulating drug. Its major action is to lower plasma triglyceride (TG)'-rich lipo- 1 . Abbreviations used in this paper: apo, apolipoprotein; apo AI, AII, B, CII, and CIII, apolipoproteins Al, AII, B, CII, and CIII; CE, proteins and to increase high density lipoproteins (HDL) in a variety of primary and secondary (e.g., diabetes mellitus, renal disease) dyslipoproteinemias including endogenous hypertriglyceridemia with and without chylomicronemia (types V and IV lipoprotein phenotypes, respectively), dysbetalipoproteinemia (type III lipoprotein phenotype), and combined hyperlipidemia (type IIB lipoprotein phenotype) (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) . Gemfibrozil also lowers low density lipoprotein (LDL) cholesterol to a lesser extent than plasma very low density lipoprotein (VLDL) and TG, and its effect on LDL becomes more pronounced on long-term treatment (1) (2) (3) (4) . Despite demonstration of its efficacy and relative lack of toxicity so far in patients treated for dyslipoproteinemias, its mechanism of action is not clear. Available evidence indicates that gemfibrozil decreases VLDL apolipoprotein (apo) B and VLDL TG synthesis (1 1, 12) . The mechanism by which it increases plasma HDL is unknown. Theoretically, this effect can be achieved by either decreased removal or by increased synthesis of HDL. Since HDL are thought to be important in reverse cholesterol transport (13) (14) (15) , knowledge regarding the mechanism(s) by which drugs increase HDL becomes important. Stimulation of HDL synthesis (and therefore transport) would be associated with increased transport of cholesterol, assuming that HDL was involved in the effilux of cholesterol from tissues to plasma for excretion. Drugs that elevate plasma HDL by decreasing HDL removal rate may not be expected, theoretically, to result in net efflux of body tissue cholesterol. These considerations have important implications in our understanding of basic mechanisms by which lipid regulating drugs may influence the atherosclerotic process. An increase in the clinical usage of such drugs is expected in view of recent clinical and coronary angiographic studies that have demonstrated reduction in coronary disease risk and lack of coronary atherosclerosis progression, respectively, by plasma lipid regulation (16) (17) (18) (19) .
The aims of this research study were (a) to determine whether gemfibrozil alters synthetic or removal rates of HDL by measuring kinetic parameters (turnover) of the major proteins of HDL, i.e., apo Al and apo All in patients with HDL switched to an isocaloric diet for at least 6 wk before the first admission to the CRC. If the patients did not achieve stable weight (±5% of body weight for at least 6 wk before week 12), they were put on "hold" position until a stable weight was achieved. Patients whose plasma TG dropped below the 90th reference percentile on weeks 6, 8, and 10 and whose HDL-C increased above the 10th reference percentile on more than one of these three visits were disqualified. At week 12, each patient was admitted to the CRC for 2 wk (weeks 12-14) to get baseline value of several research studies before gemfibrozil therapy. After these studies were completed in the CRC, gemfibrozil (600 mg twice daily) was prescribed starting at week 14. The patients were seen every 2 wk on an outpatient basis. After 8 wk of gemfibrozil treatment (weeks 14-22), each patient was readmitted for the second identical set of inpatient research studies (weeks 22-24).
Protocol in CRC. On the third day of admission to the CRC, I U of plasma was obtained from each subject by isovolumetric plasmapheresis, and EDTA, aprotinin, and phenylmethyl sulfonyl fluoride were added (23 (30) and purified as described previously (31) . Homogeneity of 121-HDL was tested by several methods, and the labeling procedure did not alter the properties of HDL as described previously (31) . Final specific radioactivity of the '251-HDL was -230 dpm/ng protein.
Apolipoprotein studies. (a) Total plasma apo Al, apo All, and apo B: Apo AI, apo All, and apo B concentrations were determined by electroimmunoassay (32) (33) (34) . (b) Measurement of specific radioactivity of apo AI and apo All: the method used was essentially that of Fidge et al. (35) . 250-300 gg of apo HDL protein was applied to 15% polyacrylamide gels containing 0.1% SDS (36) . After -3 h of electrophoresis, lines were visible in the positions of apo AI and apo All. These lines correspond to the anodic side bottom of apo Al and apo All bands, which were confirmed by a marker gel stained with Coomassie Brilliant Blue and by direct consecutive radioactive scanning of 2-mm slices from another gel. The protein bands were then sliced at 2-3 mm sections, and crushed in 2 ml of 50 mM NH4HCO3, 0.01% sodium azide, pH 8.3. The mixture was incubated for 24-30 h at 4VC and apolipoproteins were eluated. The purity of eluates was tested by 15% polyacrylamide gels containing 0.1% SDS and gel permeation chromatography. A single protein band and single elution peak (radioactivity and protein) were observed when eluates of apo AI and apo All were separately collected and applied to them. Each gel tube was subjected to low speed centrifugation and the supernate was dialyzed extensively against 50 mM NH4HCO3 solution. Protein concentration and radioactivity were measured in each sample, and specific radioactivity was obtained. These measurements were performed in duplicate or triplicate for each sample. Deviation of replicate specific radioactivity from their mean was <4.5% for apo AI and <5.4% for apo All. (c) TRL apo CII and apo CIII subspecies and their ratios: TRL (d < 1.02 g/ml) that was isolated from the plasmapheresis sample (weeks 12 and 22) was lyophilized, delipidated with acetone/ethanol (1:1 vol/vol) at -20'C (23), and the TRL urea-soluble protein was subjected to isoelectric focusing as described previously (37) .
Postheparin plasma lipolytic activities. Postheparin plasma lipolytic activity was done according to the modified method of Krauss et al. (38, 39) and as described previously (32) .
Kinetics oflipolysis of TRL. The method used was that of Johnson et al. (40, 41) and as previously described (32, 42, 43) .
Gradient gel electrophoresis (GGE) of HDL subfractions. Plasma was adjusted sequentially to a density of 1.063, 1.125, and 1.21 g/ml, ultracentrifuged, and density cuts of HDL2 (d = 1.063-1.125 g/ml) and HDL3 (d= 1.125-1.210 g/ml) were obtained (28). HDL2 and HDL3 were ultracentrifuged again at d = 1.125 and d = 1.210 g/ml, respectively, to obtain "washed" HDL subfractions and were dialysed before GGE. The molecular weight and molecular size of HDL2 and HDL3 subfractions were determined by GGE as described by Anderson et al. (44) (45) (46) 
Results
Plasma lipids, VLDL, LDL, HDL, apo AI, and apo AI. 8 wk of diet therapy (weeks 4-12) had a significant effect on the levels of plasma TG and TC in all patients (Tables I and III) . Mean plasma TtO and TC were reduced to 47% (P < 0.01) and 80% (P < 0.02) of base line, respectively. However, all patients remained hypertriglyceridemic despite maximum dietary adherence and attaining stable weight (<5% deviation between weeks 6 and 12) by the sixth visit. They proceeded to the drug treatment phase of the study. Table III shows the effects of 8-wk treatment with gemfibrozil on plasma lipids, lipoprotein cholesterol, and apo Al, apo All, and apo B. Mean plasma TG was reduced to 46% of base line (weeks 12 and 13) (P = 0.033), while mean HDL-C increased by 36% (P = 0.018) of base line. Mean LDL-C rose from a low of 87±11 mg/dl to within normal range of 1 15±15 mg/dl after gemfibrozil (P = 0.043). The effects of gemfibrozil on apolipoproteins were more significant; mean plasma apo AI, apo All, and apo B increased by 29% (P = 0.002), 38% (P = 0.001), and 18% (P = 0.030) of base line, respectively. The values shown in Table III are averages of at least five samples selected at even intervals during 2 wk of hospitalization before (weeks 12-14) and during (weeks 22-24) gemfibrozil treatment. The maximum percent deviation from the mean for HDL-C was found to be 3.9%; for apo AI it was 4.2%, and for apo All it was 3.0%. These were less than the coefficient of variation of the method and indicated that steady state conditions prevailed during the turnover studies. Note that the patients were taking isocaloric diets after they achieved and maintained constant body weight. The changes in body weight before and after 8 wk drug therapy were not significant (76.7±4.3 vs. 74.6±3.9 kg, mean±SEM). The effect of the drug was therefore additional to the effect achieved by diet.
Kinetic parameters of apo AI and apo AII metabolism.
Apo Al and apo All specific radioactivity decay curves were Fig. 1 ).
plotted against time (Fig. 1) , and mathematical analysis of the decay curves are shown in Table IV (Table V) . On gemfibrozil, TG content decreased significantly in HDL2 (P = 0.021) and HDL3 (P = 0.001), respectively. The particle size index of HDL subfractions showed that HDL2 particle size decreased in all six subjects except one, and the mean size was significantly lower (P = 0.023) after gemfibrozil. HDL3 particle size index decreased after gemfibrozil but the difference was not significant. Isolated HDL subfractions were also subjected to gradient gel electrophoresis (Fig. 2) . A major peak (peak I) was seen in density range 1.063-1.125 g/ml (Fig. 2 A) , while a major peak (peak II) and one or more minor peaks were observed in density range 1.125-1.21 g/ml (Fig. 2 B) . Molecular diameter and molecular weights of these two major peaks (peak I and peak II) decreased significantly after drug treatment (Table VI) .
Apo CII and apo CIII subspecies in TRL. Isolated TRL were also delipidated and apo CII and apo CIII subspecies were separated by analytic isoelectric focusing. The ratios of apo CIII subspecies to apo CII were determined from the densitometric scanning of the stained gels. As detailed in Table  VII 3.73±0.07 U, P = 0.034, respectively (Fig. 3) . Both Vi and F30/FO correlated positively with the particle size index (r = 0.704, P = 0.011; and r = 0.815, P = 0.001, respectively) but not with the TRL apo CIII/apo CII ratio (Fig. 4) . By analysis of covariance, the effect of particle size was corrected and the Vi and F30/FO were 9.35±0.28 vs. 7.31±0.28 U/ml and 4.10±0.1 vs. 3.83±0.10 U before and after gemfibrozil, respectively. The decline in Vi was statistically significant (P = 0.01) but not the change in F30/FO (P = 0.15).
Discussion
The results of this study demonstrate that in patients with HDL deficiency associated with familial hypertriglyceridemia, Gemfibrozil and HDL metabolism. The concentration of HDL or its apolipoproteins is controlled by synthesis, catabolism, or a combination of both. An insight into the roles of these factors in increasing plasma HDL levels after gemfibrozil is provided by turnover studies of apo AI and apo All in these patients. These turnover studies were conducted under steadystate conditions in a clinical research center with a rigid control of dietary intake. Validation of this was the observation that maximum variation from mean in HDL-C, apo Al, and apo All was less than the coefficients of variation of methods used for their quantitation.
The kinetic studies demonstrate that gemfibrozil treatment was associated with a significant increase (-1.3-fold) in the synthetic rates of apo AI and apo All. No alteration in the fractional catabolic rates of these apoproteins was found. These changes were associated with significant reductions in the size of HDL subfractions, which were assessed by gradient gel electrophoresis ( Fig. 2 and components (e.g., cholesterol, apo Al, and apo All) suggests sively show the exact route taken from first steady state to the that the number of HDL particles increased per unit plasma second. Thus, the findings of increased apo A synthetic rate volume after gemfibrozil.
and plasma concentration of smaller HDL particles after Experimental evidence indicates that apo Al and apo All gemfibrozil therapy are compatible with the inference that are synthesized by the intestine and the liver (52-55) into gemfibrozil's action in raising HDL is by stimulation of apo nascent HDL. These primordial HDL particles are thought to Al and apo All synthesis. Conclusive proof of this may require result in small HDL particles that probably correspond to the confirmation by other approaches that were beyond the scope heavier circulating HDL3 subfraction. Some evidence suggests of the current investigation.
that these particles enlarge during TRL catabolism (56, 57) . Significance of gemfibrozil's action on HDL metabolism. These considerations do not pinpoint the precise mechanism Under steady conditions, the absolute synthetic and catabolic by which gemfibrozil effected these changes. The reason is that rates (i.e., transport) of a given plasma substance are equal.
these studies, which describe two steady states, do not concluThus, gemfibrozil treatment in this study resulted in mean 8.35 . 60 ,g of lipoprotein protein were applied to each gel. After electrophoresis, the gels were stained with Coomassie Brilliant Blue, destained, and scanned as described previously (45) . The molecular weight and size of peaks obtained by scanning were determined by coelectrophoresis of pure protein standards (using high molecular weight calibration kit, Pharmacia) of known molecular weight and particle size as described by Blanche et al. (46) . increases of 126.8% and 133.6% in the absolute catabolic rate of apo AI and apo AII, respectively. Experimental evidence indicates that HDL is important in reverse cholesterol transport (13, 14) and is specifically more important than LDL in the transport of cholesterol to the liver (15). Further, apo Al is important in this process not only in free cholesterol uptake from cells (58) , but it also participates in the cholesterol esterification (59, 60) . Thus, increased apo Al transport can theoretically be associated with increased tissue cholesterol efflux and possibly increased HDL mediated cholesterol removal. Drugs that increase plasma apo Al levels by decreasing its FCR (e.g., nicotinic acid) would not theoretically be expected to be associated with increased body tissue cholesterol removal. The available evidence supports these concepts (61) (62) (63) (64) (65) (66) . However, in a recent report by Kesaniemi and Grundy (12), gemfibrozil treatment had no effect on sterol balance in a group of hyperlipidemic males who did not have familial type V dyslipoproteinemia as in this study. One explanation for this could be as follows. Gemfibrozil accelerates VLDL catabolism and the short-term result is increased plasma LDL-C and apo B concentrations. This leads to down-regulation of hepatic LDL receptors, resulting in decreased hepatic uptake After gemfibrozil therapy. § P < 0.05. II P < 0.005. n = 6, mean±SEM.
of cholesterol from LDL, so that the net effect on total sterol balance could be unchanged initially. Note that long-term effects of gemfibrozil on cholesterol balance could be quite different. In 254 patients treated for several years, LDL-C levels decreased by 23%, whereas HDL-C levels remained elevated by 23% (1) . Under these circumstances, total body cholesterol removal could be increased. Further research is clearly needed to clarify this point.
Since gemfibrozil is effective in a number of dyslipoproteinemic states, it is also possible that its effect on cholesterol balance may vary with the type of dyslipoproteinemia studied. Thus, it is important to characterize the patients and their disorders carefully before generalizations are drawn about gemfibrozil, apo A turnover, and sterol balance.
The significance of gemfibrozil in increasing apo A turnover is also related to the pathogenesis of cholelithiasis. Apo Al and apo All are secreted in bile (67) . Very recently, it was reported that apo Al and apo All in supersaturated gallbladder bile inhibit the rate of formation of solid cholesterol crystals (68) . This evidence suggests that the A apolipoproteins can prevent cholesterol gallstone formation. Thus, by increasing the turnover of A apolipoproteins, any lithogenic effect of gemfibrozil will be countered by an expected increased apo Al and apo All biliary excretion. Such a protective action on gallstone formation may not occur from administration of drugs that increase plasma apo Al and All apo levels by decreasing their removal rates.
Gemfibrozil and triglyceride metabolism. The data in this study demonstrate that in our patients, gemfibrozil not only decreased total plasma TG but also resulted in TRL that had a decreased ratio of apo Clll0/apo CII, apo CIIII/apo CII, and total apo CIII/apo CII ratio (Table VII) . TRL size after (40, 41) as described previously (32, 42, 43) . catabolism of TG rich particles is mediated by LPL, this data is consistent with the conclusion that gemfibrozil accelerated the catabolism of TG in these patients. These results are in accord with those of Nikkila et al. (7), who also found a mean increase (+ 18.1%) of postheparin LPL in 20 subjects with type IV hypertriglyceridemia. These patients were clinically different from those in our study in that they were mostly obese subjects and were not known to have fasting chylomicronemia. This mechanism of action (via LPL) of gemfibrozil in lowering TG in hypertriglyceridemic patients is in addition to previous reports (I I) and one recent study ( 12) that gemfibrozil decreases the synthesis of VLDL-apo B and TG, respectively. A very recent study on turnover of VLDL TG also showed that its FCR is increased by gemfibrozil (12). In the second approach to assess gemfibrozil's mechanism of action, TRL isolated from each patient after gemfibrozil treatment was incubated in vitro with purified bovine LPL to assess the property of TRL as a substrate of LPL. This lipolytic assay, using a fluorescence probe for measuring the initial velocity of catalysis (Vi) and the extent of catabolism (F30/ FO), has been thoroughly validated previously by Johnson et al. (40, 41) . The lipolytic rate (Vi) and extent of lipolysis (F30/ FO) was diminished in each patient studied (Fig. 3) . Superficially, this data would appear inconsistent with the observed fall in apo CIII/apo CII ratio in postgemfibrozil TRL, since apo CIII has been reported to inhibit apo CII activation of LPL (69, 70) and a decrease in the VLDL apo CIII/apo CII ratio is associated with dietary treatment of hypertriglyceridemic subjects also (71) . As background, it should be pointed out that studies showing the inhibitory properties of apo CIII are limited to use of emulsified artificial substrates and not TRL particles isolated from human subjects (69, 70). In addition to apo composition, VLDL size is an important determinant of its catabolism in vivo (72) and in vitro (73) . The data in this study indicate a significant positive correlation between TRL size index and TRL catabolic velocity (Vi), and F30/F0, which represents the extent of TRL catabolism (bottom, Fig. 4 ).
Thus, size was an important determinant of TRL catabolism by LPL, but not TRL apo CIII/CII ratio, which did not correlate significantly with the parameters of lipolysis (top, Fig. 4 ). When the data for particle size was corrected by analysis of covariance, Vi of postgemfibrozil TRL remained significantly lower. The exact explanation of this observation is not clear. Since gemfibrozil decreases VLDL TG and apo B synthesis (1 1, 12) , it is possible that it also alters the property of VLDL as a substrate for LPL. Future experiments using TRL subfractions of equal size are necessary to confirm this finding. Thus, the evidence so far indicates that the major mechanisms by which gemfibrozil lowers plasma TG levels are by decreasing VLDL synthesis and by increasing TRL catabolism by stimulating LPL. Apo CIII and apo CII changes may not be important in its TG lowering effect.
In summary, in patients with HDL deficiency associated with familial hypertriglyceridemia, we have documented increased turnover of apo Al and apo All, the major proteins of HDL, resulting from gemfibrozil, the only drug known to have this effect at present. Additional research is necessary to determine whether drug-induced increased apo A turnover is associated with increased reverse cholesterol transport and/or protection from cholesterol gallstones. Institutes of Health (NIH RR 00068-15), and by a research grant from the Warner-Lambert/Parke Davis Co.
